JUN 28, 2017 07:00 AM PDT
Analytical methods to measure empty and full AAV particles
7 16 3367

Speakers:
  • Head of Analytical Development, Genethon
    Biography
      Christine Le Bec joined Genethon in 1997 and currently heads the Analytical Development Department. She is responsible for developing bioassays and setting up advanced analytical tools used for characterization and in release, in-process testing of gene therapy products at early stage development. She has implemented at Genethon the analytical ultracentrifugation as a routine testing to assess the AAV vector quality and the manufacturing consistency. As a research scientist, she has been involved in AAV and plasmid engineering mainly on the design of novel vectors and on the regulation of gene expression.

      Before joining Genethon, she obtained her PhD in Bio-Organic Chemistry from Université Pierre et Marie Curie (Paris VI) in 1993. She worked as a postdoctoral researcher at Thomas Jefferson University (Philadelphia, US) and then at Institut Pasteur (Paris, France) in the field of synthesis, structural analysis and in vitro evaluation of antisense DNA as therapeutic agents for cancer and AIDS.

    Abstract:

    DATE: June 28, 2017
    TIME: 7:00am PT, 10am ET

    As gene therapy approaches usually require large amounts of AAV vectors for clinical use, few manufacturing processes have been reported to provide high titer and potent quantities of products.
    The dose control of AAV vectors is commonly established on titration methods relying either on the quantitation of DNA (viral genome) or transgene expression following cell transduction (infectious genome). However, AAV vector lots are generally a heterogeneous mixture of empty particles (i.e. do not contain DNA) and full particles (i.e. contain DNA). Therefore, it could be considered that empty particles are product related impurities, which can impact on the immunogenicity profile of the product when high doses are administered to patients.

    Different indirect methods can be used to establish the ratio between full and empty AAV particles. The quantification of full capsids is performed by using qPCR based technology. The total particles can be evaluated by an ELISA assay, spectrometric analysis, ion-exchange chromatography or SDS-PAGE. However, these methods have limitations and are not applicable to all serotypes without performing a new development.

    Using analytical ultracentrifugation approach, we have developed a method to quantify simultaneously empty and full AAV particles as well as intermediate species containing fragmented or incomplete vector genome. We have applied this technique to AAV lots of different serotypes, several sizes of transgene and different process of production. Several examples of AAV vectors analysis will be presented showing that AUC could be implemented as a routine test to monitor AAV product quality and manufacturing consistency.


    Show Resources
    Loading Comments...